¶ Myeloid-derived suppressor cells
¶ Definition
Myeloid-Derived Suppressor Cells (MDSCs) are a heterogeneous population of pathologically activated immature myeloid cells characterized by potent immunosuppressive capabilities. Under physiological conditions, these cells remain in bone marrow as precursors to macrophages, dendritic cells, and neutrophils, but under pathological stress—cancer, chronic infections, chronic inflammation, severe obesity, and cachexia—they expand systemically, migrate to peripheral tissues, and suppress T cells, NK cells, and other immune effectors through multiple metabolic and signaling mechanisms.
¶ Picture It
Think of MDSCs as an emergency construction crew that's supposed to stay on standby at headquarters (bone marrow) until needed for repairs. In healthy tissue, they're just apprentices waiting to mature into specialized workers—some will become demolition experts (neutrophils), others renovation managers (macrophages), and some architects (dendritic cells).
But when there's chronic trouble—a tumor setting up shop, persistent infection, or ongoing inflammatory fire—the alarm system gets hijacked. Instead of maturing properly, these apprentices get rushed to the scene half-trained and are given a different job: shut down the local security force. They arrive at the worksite and start stealing the tools (depleting L-Arginine), cutting power lines (generating Reactive Oxygen Species), and telling the actual security guards (T cells) to stand down by flashing fake credentials (expressing PD-L1, secreting IL-10).
The cruel twist? In severe cachexia, even this emergency crew can't leave headquarters—they're trapped in the bone marrow by broken exit doors, which contributes to mortality because the body loses even this dysfunctional immune response. Meanwhile, in cancer, these cells are actively recruited by the tumor like double agents, creating a protective shield that prevents immune surveillance from doing its job.
¶ Mechanism
¶ MDSC Generation and Expansion
Under homeostatic conditions, hematopoietic stem cells differentiate into common myeloid progenitors in bone marrow, which mature into functional myeloid cells. Pathological conditions trigger a cascade that blocks this maturation:
Expansion signals:
- Tumor-derived factors: GM-CSF, G-CSF, M-CSF
- Inflammatory cytokines: Interleukin-6 (IL-6), IL-1β, TNF-α
- VEGF and PGE2 from tumor microenvironment
- Hypoxic signals via HIF-1 activation
Signal transduction:
GM-CSF/G-CSF → JAK2 activation → STAT3 phosphorylation → upregulation of S100A8/A9 proteins (inflammatory alarmins) → sustained immature phenotype + expansion
IL-6 → IL-6R/gp130 → JAK-STAT → STAT3 nuclear translocation → transcription of C/EBPβ → blocks myeloid differentiation while promoting MDSC accumulation
¶ MDSC Subsets
Polymorphonuclear MDSCs (PMN-MDSCs):
- 80-90% of total MDSCs in most pathological conditions
- Phenotype: CD11b⁺CD33⁺CD15⁺CD66b⁺HLA-DR⁻/low (human); CD11b⁺Ly6G⁺Ly6Clow (mouse)
- Morphologically resemble neutrophils
- Primary mechanism: Reactive Oxygen Species production via NADPH oxidase
Monocytic MDSCs (M-MDSCs):
- 10-20% of MDSCs
- Phenotype: CD11b⁺CD33⁺CD14⁺HLA-DR⁻/low (human); CD11b⁺Ly6G⁻Ly6Chi (mouse)
- Morphologically resemble monocytes
- Primary mechanisms: arginase-1 production, NO synthesis, immunosuppressive Cytokines
¶ Immunosuppressive Mechanisms
Metabolic depletion pathway:
- STAT3/C/EBPβ upregulate ARG1 gene
- Arginase-1 enzyme hydrolyzes L-Arginine → ornithine + urea
- Local L-Arginine drops below 50 µM threshold
- T cells cannot synthesize arginine (lack argininosuccinate synthase)
- Reduced arginine → impaired CD3ζ chain expression → loss of TCR signaling
- T cell arrest in G0-G1 phase, cannot proliferate
Nitrosative stress pathway:
- IFN-γ + LPS → NF-κB → iNOS transcription
- iNOS converts L-Arginine + O₂ → NO + Citrulline
- NO production reaches 1-10 µM in MDSC microenvironment
- NO + superoxide (from NADPH oxidase) → peroxynitrite (ONOO⁻)
- Peroxynitrite nitrates tyrosine residues on:
- TCR components → impaired T cell activation
- MHC molecules → reduced antigen presentation
- CD8 molecules → defective cytotoxic function
ROS generation:
PMN-MDSCs activate NADPH oxidase (NOX2) → superoxide production (O₂⁻) → hydrogen peroxide (H₂O₂) → oxidative damage to T cell membrane lipids and proteins → T cell dysfunction and apoptosis
Immune checkpoint expression:
MDSCs constitutively express PD-L1 (CD274) on surface → binds PD-1 on activated T cells → recruits SHP-2 phosphatase → dephosphorylates TCR signaling molecules → T cell exhaustion
Regulatory T cell induction:
MDSCs secrete IL-10 + TGF-beta + produce retinoic acid → convert conventional CD4⁺ T cells into Treg cells (FoxP3⁺) → amplifies immunosuppression
¶ Trafficking Defects in Cachexia
In severe cachexia, despite bone marrow expansion of MDSCs:
- Loss of CXCR4 receptor downregulation (normally required for bone marrow egress)
- Impaired response to peripheral chemokines (CXCL1, CCL2)
- Defective integrin expression → cannot adhere to endothelium
- Result: MDSCs trapped in bone marrow → paradoxical immune paralysis despite expansion
- Contributes to sepsis susceptibility and mortality in cachectic patients
¶ Clinical Significance
MDSCs represent a critical concept for understanding the paradox of immunosuppression within inflammation—a hallmark of chronic disease that violates traditional immune categorization. In cPNI practice, MDSC biology illuminates why patients with chronic inflammatory conditions (obesity, metaflammation, inflammatory bowel disease) simultaneously exhibit immune hyperactivity (elevated IL-6, CRP) and immune incompetence (recurrent infections, poor vaccine responses, cancer susceptibility).
Cancer immunotherapy resistance:
MDSCs are the primary cellular barrier to checkpoint inhibitor therapy and CAR-T cell treatments. Tumor-infiltrating MDSCs can comprise 30-40% of immune cells in solid tumors, creating an immunosuppressive shield. Strategies targeting MDSCs (gemcitabine, all-trans retinoic acid, phosphodiesterase-5 inhibitors) are being investigated to restore anti-tumor immunity.
Chronic infection paradox:
In persistent viral infections (HIV, HCV, COVID-19) and chronic bacterial infections, sustained antigen exposure drives MDSC expansion. This creates a vicious cycle: inflammation generates MDSCs → MDSCs suppress pathogen-specific T cells → pathogen persists → more inflammation. This explains why some Long COVID patients show both elevated inflammatory markers and poor adaptive immune responses.
Metabolic dysfunction:
In obesity and Type 2 Diabetes, adipose tissue inflammation expands MDSCs systemically. Visceral fat-resident MDSCs contribute to insulin resistance through TNF-α and IL-6 secretion, while simultaneously suppressing anti-inflammatory Treg cells. MDSC accumulation in adipose tissue correlates with HbA1c levels and predicts metabolic complications.
Cachexia mortality:
The bone marrow trapping of MDSCs in severe cachexia represents a terminal failure of immune trafficking. Patients with cancer cachexia showing high bone marrow MDSC counts but low circulating MDSCs have significantly worse prognosis (median survival 
months). This phenotype indicates breakdown of fundamental immune mobilization mechanisms.
Intervention framework (Metamodel 5 - Clinical Practice):
- Reduce MDSC generation: Address upstream drivers (tumor burden, chronic infection, visceral adiposity, chronic stress)
- Block MDSC function: High-dose omega-3 fatty acids (EPA/DHA) compete with arachidonic acid, reducing PGE2-driven MDSC activation
- Promote MDSC differentiation: All-trans retinoic acid (ATRA) induces MDSC maturation into functional dendritic cells and macrophages
- Deplete MDSCs: Gemcitabine (low-dose) selectively kills MDSCs; tyrosine kinase inhibitors block MDSC survival signals
- Restore metabolic balance: L-Arginine supplementation (6-10g/day) can partially overcome arginine depletion, though MDSCs adapt by upregulating arginase
Clinical biomarkers:
- Flow cytometry: CD11b⁺CD33⁺HLA-DR⁻/low frequency in peripheral blood
- Functional assays: T cell suppression capacity
- Indirect markers: Low arginine/citrulline ratio (<0.7), elevated arginase activity in serum
- Threshold: >5% MDSCs of total PBMCs indicates pathological expansion
¶ Key Facts
- MDSCs identified by CD11b⁺CD33⁺HLA-DR⁻/low in humans; Gr-1⁺CD11b⁺ in mice (though Gr-1 antibody cross-reacts with Ly6G and Ly6C)
- Two functional subsets: PMN-MDSCs (granulocytic, 80-90%) produce ROS; M-MDSCs (monocytic, 10-20%) produce arginase-1 and NO
- Arginase-1 depletes L-Arginine below 50 µM → blocks T cell CD3ζ chain expression → T cell cycle arrest
- iNOS produces NO at 1-10 µM concentrations in MDSC microenvironment → nitrosative stress on immune cells
- Peroxynitrite (formed from NO + superoxide) nitrates tyrosine residues on TCR and MHC molecules → impaired antigen recognition
- MDSC frequency >5% of peripheral blood mononuclear cells indicates pathological expansion
- In tumor microenvironment, MDSCs can represent 30-40% of total immune infiltrate
- STAT3 is master transcription factor driving MDSC expansion and function (constitutively active in >70% of tumor-associated MDSCs)
- S100A8/A9 proteins (calprotectin) serve as autocrine/paracrine signals sustaining MDSC expansion
- In severe cachexia, MDSCs fail to egress from bone marrow despite systemic expansion → contributes to mortality from sepsis
- All-trans retinoic acid (ATRA) at 150 mg/m² can induce MDSC differentiation into mature myeloid cells
- High-dose omega-3 (2-4g EPA+DHA daily) reduces PGE2-mediated MDSC activation and trafficking
¶ Connections
- T cell exhaustion — MDSCs directly induce exhaustion through PD-L1/PD-1 interaction and sustained antigen presentation in suppressive context
- Cancer — MDSCs expand in tumor microenvironment, block anti-tumor immunity, promote angiogenesis via VEGF, and facilitate metastasis through matrix metalloproteinase production
- chronic inflammation — Sustained inflammatory cytokines (IL-6, IL-1β, TNF-α) drive MDSC expansion while MDSCs perpetuate inflammation through paradoxical cytokine production
- cachexia — In severe cachexia, MDSCs become trapped in bone marrow due to defective CXCR4 downregulation and impaired trafficking mechanisms, contributing to immune paralysis and mortality
- immunosuppression — MDSCs are principal cellular mediators of pathological immune suppression across cancer, chronic infection, and metabolic disease
- Treg cells — MDSCs promote Treg expansion through IL-10, TGF-β, and retinoic acid production, amplifying regulatory networks
- metaflammation — Chronic metabolic inflammation in obesity drives systemic MDSC expansion; visceral adipose tissue serves as MDSC reservoir
- obesity — Adipose tissue inflammation generates MDSCs that contribute to insulin resistance while suppressing protective Tregs
- Type 2 Diabetes — MDSC accumulation in visceral fat correlates with HbA1c and insulin resistance; MDSCs impair pancreatic β-cell function
- Reactive Oxygen Species — PMN-MDSCs generate ROS via NADPH oxidase, causing oxidative damage to T cell membranes and signaling molecules
- L-Arginine — MDSCs deplete arginine through arginase-1, blocking T cell proliferation; arginine supplementation partially rescues T cell function
- STAT3 — Master transcription factor driving MDSC generation, survival, and immunosuppressive function; constitutively phosphorylated in tumor-associated MDSCs
- IL-10 — MDSCs secrete IL-10 creating immunosuppressive microenvironment and inducing Treg differentiation
- Interleukin-6 — IL-6 drives MDSC expansion via JAK-STAT3 signaling; MDSC frequency correlates with serum IL-6 levels in inflammatory conditions
- Long COVID — MDSC expansion documented in persistent COVID-19, contributing to immune dysregulation and T cell suppression
- neutrophils — PMN-MDSCs morphologically and phenotypically resemble neutrophils but are functionally immunosuppressive rather than antimicrobial
- monocytes — M-MDSCs resemble monocytes but express high arginase-1 and iNOS, suppressing rather than activating adaptive immunity
- HIF-1 — Hypoxia-inducible factor drives MDSC accumulation in tumors and ischemic tissues; HIF-1α stabilization enhances MDSC immunosuppressive capacity
- NK cells — MDSCs suppress NK cell cytotoxicity through membrane-bound TGF-β and direct cell contact via NKp30 ligand interactions
- macrophages — Under normalizing conditions (e.g., ATRA treatment), MDSCs can differentiate into functional macrophages; tumor-associated macrophages and MDSCs cooperate in creating immunosuppressive niches
- dendritic cells — M-MDSCs can differentiate into tolerogenic dendritic cells; MDSC-derived exosomes transfer functional suppressive capacity to DCs
- VEGF — Tumor-derived VEGF drives MDSC expansion and trafficking; VEGF inhibitors partially reduce MDSC accumulation
- PGE2 — Prostaglandin E2 from tumors and inflamed tissues activates MDSCs via EP2/EP4 receptors, enhancing arginase-1 and COX-2 expression
- CXCR3 — PMN-MDSCs express CXCR3 and migrate to inflamed tissues following CXCL9/CXCL10 gradients; defective in cachexia
- Hypoxia — Tumor hypoxia expands MDSCs via HIF-1α and adenosine accumulation; MDSCs thrive in hypoxic niches
- Insulin resistance — Adipose MDSCs secrete TNF-α and IL-6, impairing insulin signaling in adipocytes and hepatocytes
- inflammatory bowel disease — MDSCs accumulate in intestinal mucosa during IBD flares, suppressing beneficial Th1 responses while paradoxically maintaining inflammation
¶ Module References
- Module 1
- Module 8